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Patients with cancer frequently experience a debilitating and
terminal weight-losing syndrome known as cancer cachexia with
depletion of both adipose tissue and skeletal muscle mass. Various
mediators have been postulated to be responsible for this condi-
tion, including cytokines such as tumour necrosis factor alpha
(TNF-a), interleukin-6 (IL-6) and interferon gamma (IFN-g),
together with tumour-produced catabolic factors acting on adipose
tissue and skeletal muscle (Tisdale, 1997).
We have recently isolated and purified a sulphated glycoprotein
of apparent molecular weight 24 000 from both a cachexia-
inducing murine tumour (MAC16) and from the urine of patients
with cancer cachexia (Todorov et al, 1996a; Cariuk et al, 1997).
This material produces a state of cachexia when administered to
non tumour-bearing mice, with specific depletion of the non-fat
carcass mass (Todorov et al, 1996a). Unlike the cytokines the
sulphated glycoprotein produced direct proteolysis in isolated
skeletal muscle (Lorite et al, 1997), and for this reason it has been
called proteolysis-inducing factor (PIF). The specificity of the
action of PIF could be demonstrated by the neutralization of the
catabolic action on muscle by a monoclonal antibody originating
from the splenocytes of mice transplanted with the MAC16
tumour (Todorov at al, 1996b). In addition, protein degradation
initiated in vitro by PIF was aboloshed by using skeletal muscle
from mice treated with the polyunsaturated fatty acid, eicosapen-
taenoic acid (EPA) (Lorite et al, 1997), which has been shown to
attenuate the development of cachexia, not only in the MAC16
model (Tisdale and Beck, 1991), but also in patients with unre-
sectable pancreatic cancer (Wigmore et al, 1996).
In vivo studies with both murine (Todorov et al, 1996a) and
human (Cariuk et al, 1997) PIF demonstrated a marked depression
in blood glucose levels, in addition to the loss of lean body mass,
suggesting an effect on glucose utilization. This study investigates
the effect of PIF on glucose utilization by different tissues in vivo
using the 2-deoxyglucose tracer technique and the effect of EPA
and the monoclonal antibody on this process.
MATERIALS AND METHODS
Animals
Pure strain NMRI mice were obtained from our own inbred colony
and were fed a rat and mouse breeding diet (Special Diet Services,
Witham, UK). Fragments of the MAC16 tumour, excised from
donor animals with established weight loss, were implanted into
the flanks of NMRI mice by means of a trochar (Beck and Tisdale,
1987). Tumours, which were excised from mice when they
weighed between 0.1 and 0.6 g and before weight loss exceeded
25% of the total body weight, were used to prepare PIF. Solid
MAC16 tumours were homogenized followed by ammonium
sulphate precipitation (40% w/v), centrifuged and the supernatant
was subject to affinity chromatography as previously described
(Todorov et al, 1996b).
Chemicals
2-Deoxy-D-[2,6-3H]glucose ([3H]2DG; sp.act. 42 mCi mmol–1)
and 2-deoxy-D-[ 1-14C]glucose ([14C]2DG; sp.act. 56 mCi mmol–1)
were purchased from Amersham (International, Bucks, UK).
Blood glucose was determined using the o-toluidine reagent kit
from Sigma Chemical Co (Dorset, UK). EPA (95%, expressed as a
percentage of fatty acid methyl esters prepared) was kindly
donated by Scotia Pharmaceuticals Ltd. (Stirling, UK). Hi-safe 3
scintillation fluid was from Fisons Scientific Equipment
(Leicestershire, UK).
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Summary The effect of a proteolysis-inducing factor (PIF), produced by cachexia-inducing tumours on glucose utilization by different tissues
and the effect of pretreatment with the polyunsaturated fatty acid eicosapentaenoic acid (EPA), has been determined using the 2-
deoxyglucose tracer technique. Mice receiving PIF showed a profound depression of body weight (2.3 g) over a 24-h period, which was
completely abolished by pretreatment with a monoclonal antibody to PIF or by 3 days pretreatment with EPA at 500 mg kg–1. Animals
receiving PIF exhibited a marked hypoglycaemia, which was effectively reversed by both antibody and EPA pretreatment. There was an
increase in glucose utilization by brain, heart and brown fat, but a decrease by kidney, white fat, diaphragm and gastrocnemius muscle after
administration of PIF. Changes in organ glucose consumption were attenuated by either monoclonal antibody, EPA, or both. There was a
decrease in 2-deoxyglucose uptake by C2C12 myoblasts in vitro, which was attenuated by EPA. This suggests a direct effect of PIF on glucose
uptake by skeletal muscle. These results suggest that in addition to a direct catabolic effect on skeletal muscle PIF has a profound effect on
glucose utilization during cachexia.
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The extent of glucose utilization by different tissues was deter-
mined in female NMRI mice after administration of PIF using the
2-deoxyglucose tracer technique (Meszaros et al, 1987), except
that animals were not starved. One group of mice received EPA,
per orally (p.o.) at 500 mg–1 kg for 3 days prior to PIF, whilst
another received monoclonal antibody, prepared as previously
described (Todorov et al, 1996b), by intraperitoneally (i.p.) admin-
istration of 0.8 mg protein in 100 ml phosphate-buffered saline
(PBS) 24 h before the first injection of PIF. Animals were admin-
istered PIF (7.5 mg protein administered by injection into the tail
vein) at 0, 1.5, 3.0, 4.5 and 6.0 h whilst controls were administered
PBS by the same route. At 24 h after the first injection of PIF all
animals were injected i.v. with 30 mCi [3H]2DG, and to determine
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Figure 1 Effect of PIF on body weight of female NMRI mice either administered alone (l) or after pretreatment with monoclonal antibody (l l) (32 mg kg–1) (A)
or EPA (D) (500 mg kg–1) (B). Control mice (´) in both groups received PBS, while in B an additional control group received EPA (s) (500 mg kg–1). PIF was
administered at time 0, 1.5, 3.0, 4.5 and 6.0 h as described in Methods. The starting weight of the mice was 24.85 ± 0.38 g. Weights are expressed as mean ±
s.e.m. for five animals per group. Differences from the control group were determined using two-way ANOVA followed by Tuckey’s test and are indicated as ‘a’
P < 0.01 and ‘b’ P < 0.005the retention of 2-deoxyglucose 6-phosphate (2DGP) by different
tissues a second i.v. injection of 3 mCi [14C]2DG was administered
35 min after the injection of [3H]2DG. Blood was removed from
animals under anaesthesia by cardiac puncture at 60 min and the
glucose concentration in whole blood was determined using the o-
toluidine reagent kit. The concentration of radioactivity in the
blood was determined on deproteinized neutralized samples with a
dual 3H/14C analyser. The accumulation of phosphorylated metabo-
lites of 2DG was measured in selected tissues. Each tissue was
homogenised in 0.4–0.8 ml per 100 mg tissue of ice-cold 0.5 N
perchloric acid, followed by centrifugation. The supernatant was
neutralized to pH 7 with 10% w/v potassium hydroxide and the
radioactivity was determined after the removal of the insoluble
potassium perchlorate. This gave a measure of the total 2DG
radioactivity in the tissue. 2DGP was removed from the neutral
extract by precipitation with zinc sulphate/barium hydroxide and
the difference between the total radioactivity of the neutral extract
and that after removal of 2DGP represented the 2DGP content of
the tissue.
Glucose utilization was calculated from the equation (Meszaros
et al, 1987):
R g = C m * (T)/L CT
o ∫ C p*C p · d t
where Rg is the tissue glucose metabolic rate (nmol min–1 g–1),
Cm*(T) is the concentration of phosphorylated metabolites of
2DG in the tissue (dpm g–1) at t = 60 min, Cp is the blood glucose
(nmol ml–1), Cp* is the concentration of [3H]2DG in the blood
(dpm ml–1) and LC (lumped constant) is a dimensionless correc-
tion factor for discrimination against 2DG in glucose metabolic
pathways. This was determined by the method of Ferre et al (1985)
and found to be 0.46 in NMRI mice (Mahony and Tisdale, 1990).
Effect of PIF on glucose utilization in vitro
Experiments were performed on the C2C12 mouse myoblast cell
line in the subconfluent state. Cells were seeded in 60 ´ 15 mm
petri dishes at 4 ´ 104 cells ml–1 in 2 ml Dulbecco’s modified
Eagles medium supplemented with 12% fetal calf serum, 1% non-
essential amino acids and 1% pencillin–streptomycin and left for
24 h. Some cultures received 50 mM EPA (dissolved g for g in
bovine serum albumin then mole for mole in sodium bicarbonate
and sonicated to produce micelles). After 2 h PIF was added in
phosphate-buffered saline (PBS) and the cultures left for 24 h. The
medium was aspirated off and the cells were washed once with
Krebs–Ringer bicarbonate buffer, pH 7.2, and incubated in 1 ml of
the Krebs buffer for 30 min at 37°C together with 10 ml [3H]2DG
(sp. act, 2 mCi mmol–1). The cells were washed three times with
ice-cold PBS and incubated on ice for at least 1 h with 1 M sodium
hydroxide (1 ml per dish). The radioactivity was determined in Hi-
safe 3 scintillation fluid using a 2000 CA Tri-Carb liquid scintilla-
tion analyser.
RESULTS
The effect of PIF administered either alone or after pretreatment
with the monoclonal antibody (Figure 1A) or EPA (Figure 1B) on
the body weight of mice was determined over a 24 h period. There
was a rapid decrease in body weight of mice receiving PIF, which
first became significant within 3 h after the first injection and
reached 2.3 g by 24 h. Previous studies (Todorov et al, 1996a;
Lorite et al, 1997) have shown that this loss of body weight is due
to loss of the non-fat carcass mass, predominantly skeletal muscle.
Pretreatment of mice with either the monoclonal antibody (Figure
1A) or EPA (Figure 1B) completely abolished the cachectic effect
of PIF and produced a weight loss profile indistinguishable from
PBS- or EPA-treated control groups. Both the antibody and EPA
were equieffective in reversing the effect of PIF on body weight
loss.
In order to investigate glucose dynamics in organs of mice
treated with PIF, glucose utilization was investigated by the 2DG
tracer method. Animals treated with PIF showed a marked hypo-
glycaemia within 24 h of the first injection (Table 1), which was
effectively reversed with both antibody and EPA pretreatment. The
tissue glucose metabolic rate (Rg) of saline control and PIF-treated
animals, with or without antibody and EPA pretreatment, together
with EPA controls is shown in Table 2. The Rg values were lower
than those we have previously reported (Mahony and Tisdale,
1990; Mulligan and Tisdale, 1991) since the animals were not
starved overnight, and throughout the experiment because of the
profound weight loss induced by PIF. There were no differences in
food intake (2.5, 2.7 and 2.8 g per mouse for control, PIF and PIF
+ EPA groups respectively) between the groups as previously
reported (Todorov et al, 1996a; Lorite et al, 1997). There were
major changes in the Rg values in a number of organs after admin-
istration of PIF, which were attenuated by either the antibody or
EPA or both (Table 2).
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Table 1 Effect of PIF on blood glucose levels in female NMRI micea
Group Glucose nmol ml–1 (mean ± s.e.m.)
PBS 9.51 ± 0.45
EPA 11.54 ± 0.79b
PIF 6.51 ± 0.57
PIF + Ab 8.57 ± 0.30c
PIF + EPA 10.35 ± 0.38c
aBlood glucose values were determined 24 h after the first injection. The
experimental procedure is described in Methods and the legend to Figure 1.
Statistical analysis was by Student’s t-test with Bonferroni correction.
bP < 0.005 from PBS control. cP < 0.005 from PIF. PBS, phosphate-buffered
saline; EPA, eicosapentaenoic acid; PIF, proteolysis-inducing facter; Ab,
antibody.
Table 2 Tissue glucose metabolic rate (Rg)
Tissue Control PIF PIF + Ab EPA PIF + EPA
Brain 70 ± 10c 230 ± 10f 80 ± 10c 200 ± 60b,f 80 ± 10c
Heart 84 ± 9c 170 ± 8f 137 ± 11c,f 138 ± 18c,f 60 ± 5c,d
Liver 48 ± 2 47 ± 3 14 ± 3c,e 62 ± 6 25 ± 4a,e
Kidney 52 ± 3a 26 ± 4d 24 ± 4c,e 92 ± 13c,f 55 ± 6b
Spleen 61 ± 3 43 ± 5 20 ± 1a,f 66 ± 4a 47 ± 3
White fat 30 ± 21 1   ± 1 31 ± 10 33 ± 2a 47 ± 6c
Brown fat 75 ± 3c 111 ± 7f 50 ± 3c,d 98 ± 16d 100 ± 12d
Diaphram 174 ± 25c 53 ± 5f 61 ± 3f 168 ± 16c 201 ± 16c,d
Gastrocnemius 89 ± 10c 17 ± 1f 41 ± 2a,f 99 ± 11c 90 ± 10c
Rg values are expressed as nmol glucose g–1 min–1 and are given as mean ±
s.e.m. Values were determined 24 h after the first injection of PIF. Statistical
analysis was performed using two-way ANOVA followed by Tuckey’s test.
Differences are expressed as aP < 0.05, bP < 0.01 and cP < 0.005 from the
PIF-treated group and eP < 0.01 and fP < 0.005 from the PBS control group.
PIF, proteolysis-inducing factor, Ab, antibody; EPA, eicosapentaenoic acid.Brain
There was a threefold increase in the Rg value for glucose in
animals treated with PIF, which was reduced to control values in
mice pretreated with both EPA and antibody, despite the elevation
in Rg value for mice treated with EPA alone.
Heart
There was a twofold elevation in the Rg value for glucose in mice
treated with PIF, which was reduced to below control value by
EPA, despite a significant elevation in Rg value producted by EPA
alone. There was a significant reduction in Rg value produced by
the antibody, although this still remained elevated compared with
saline treated controls.
Liver
Although PIF alone produced no alteration in the Rg value for
glucose, the combination of PIF with either the antibody or EPA
caused a significant reduction in Rg value to below that of control
animals.
Kidney
There was a 50% reduction in the Rg value for glucose in animals
treated with PIF, which was normalized to the control value in
mice pretrated with EPA, but not the antibody. Again, EPA alone
produced a significant increase in the Rg value.
Spleen
There was a small decrease in the Rg value in PIF-treated animals,
which did not reach significance. The combination of PIF and the
antibody produced a significant decrease in Rg value to below that
of the control.
White fat
There was a decrease in Rg value in animals treated with PIF,
although this was not significantly different from the control.
Animals pretreated with EPA before receiving PIF had a Rg value
significantly higher than those receiving PIF alone.
Brown fat
There was a significant elevation in the Rg value in animals
receiving PIF, which was reduced to below the control level by the
antibody, but not by EPA.
Diaphragm
There was a large reduction in the Rg value produced by PIF,
which was normalized by EPA, but not by the antibody.
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Figure 2 Effect of PIF on uptake of 2-deoxyglucose into C2C12 myoblasts in vitro. Cells were incubated with PIF with (n) or without (´) pretreatment with 50 mM
EPA. Results are shown as mean ± s.e.m. where n = 9. Differences from controls are indicated as ‘a’ P < 0.05, while differences from the PIF alone treated
group are shown as ‘b’ P < 0.05Gastrocnemius muscle
There was an 80% reduction in the Rg value in animals treated
with PIF, which was attenuated by both the antibody and EPA.
PIF produced a decrease in uptake of 2-deoxyglucose in C2C12
myoblasts in vitro, a model of skeletal muscle (Figure 2). This
effect was maximal at 10 nM PIF and was not seen in cells
pretreated with EPA. This suggests that PIF has a direct inhibitory
effect on glucose consumption by diaphragm and gastrocnemius
muscle in vivo.
DISCUSSION
There have been very few reports on glucose oxidative metabolism
in cachectic cancer patients. Waterhouse and Kemperman (1971)
observed that in the post-adsoptive state both cachectic cancer
patients and controls showed similar oxidative metabolism from
glucose and fatty acids. However, after a glucose load, oxidative
metabolism from glucose in the control subjects increased by 62%
and that from fatty acids fell by 70%, but there was little change in
the oxidative metabolism pattern in the cachectic patients. This
suggests that weight-losing cancer patients may maintain a fasting
oxidative metabolism profile, even in the presence of a glucose
load. There was also a slower glucose disappearance from the
blood after a glucose load in the cachectic cancer patients. This
may be indicative of reduced uptake of glucose by peripheral
tissues as also observed by other workers (Schein et al, 1979),
suggesting a degree of glucose intolerance in patients with cancer
cachexia. Reduced utilization of glucose by peripheral tissues was
also suggested from the observation of a decrease in activity of
glycolytic and glucose oxidative enzymes in biopsies from rectus
abdominal muscle of patients with heterogenous malignancies
(Lundholm et al, 1976).
The results of the present investigation suggest profound
changes in glucose homeostasis after administration of PIF, with
hypoglycaemia and specific tissue alterations in glucose consump-
tion. Hypoglycaemia has previously been reported with both
human (Nolop et al, 1987) and experimental tumours such as the
MAC16 adenocarcinoma (McDevitt and Tisdale, 1992) and
appears to be unrelated to food intake, glucose consumption by the
tumour or insulin-like growth factors (either IFG-I or IGF-II)
produced by tumours. Insulin levels have been found to be low in
cases of tumour-associated hypoglycaemia (Bibby et al, 1987) and
the production of an insulin-like factor by the tumour was
suggested as the cause of the enhanced peripheral glucose uptake.
The present results suggest that this mediator is PIF, although
glucose consumption was found to be significantly increased only
in brain, brown fat and heart, while in skeletal muscles, such as
gastrocnemius and diaphragm, glucose consumption was found to
be significantly decreased. This is consistent with the observation
that PIF produces a significant decrease in the weight of the soleus
and gastrocnemius muscles, while having no effect on the weight
of the heart (Lorite et al, 1998).
Although the action of PIF on body weight loss appears to be
mediated through skeletal muscle protein degradation (Todorov et
al, 1996b), an increased glucose consumption by brown fat is
indicative of an increased energy expenditure, which may play a
contributory role in the overall development of weight loss
induced by PIF. EPA also increased glucose consumption in brown
fat, which would correlate with the report of a marked stimulation
of brown adipose tissue (BAT) thermogenic activity by n-3
polyunsaturated fatty acids (Oudart et al, 1997).
The effect of PIF on both body weight loss and glucose utiliza-
tion was attenuated by treatment both with a monoclonal antibody
to PIF and EPA showing the specificity of the process. EPA has
been shown to inhibit the biological activity of both a lipid mobi-
lizing factor (Tisdale and Beck, 1991) and PIF (Lorite et al, 1997)
in bioassays, as well as attenuating the development of cachexia in
the MAC16 model. The ability of EPA to prevent the development
of weight loss initiated by PIF confirms a direct antagonistic effect
rather than by an effect on the biosynthesis of PIF. PIF appears to
have a direct inhibitory effect on glucose consumption by skeletal
muscle, since uptake of 2-deoxyglucose by C2C12 myoblasts in
vitro was also inhibited by PIF. This suggests that pertubations in
glucose homeostatis in animals receiving PIF is not due to release
of cytokines.
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